MedPath

Timolol

Generic Name
Timolol
Brand Names
Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
Drug Type
Small Molecule
Chemical Formula
C13H24N4O3S
CAS Number
26839-75-8
Unique Ingredient Identifier
5JKY92S7BR
Background

Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.

Indication

Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.

Associated Conditions
Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
Associated Therapies
-
Clinical Trials
Related News

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 2
Completed
Conditions
Ocular Hypertension
Open Angle Glaucoma
Interventions
Drug: BOL-303259-X
Drug: Timolol maleate
First Posted Date
2012-10-16
Last Posted Date
2018-09-04
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
25
Registration Number
NCT01707381
Locations
🇺🇸

University of California San Diego, La Jolla, California, United States

Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%

Phase 1
Withdrawn
Conditions
Optic Neuropathy, Ischemic
Ischemic Optic Neuropathy
Anterior Ischemic Optic Neuropathy
Optic Neuropathy, Anterior Ischemic
Interventions
Drug: Timolol maleate
First Posted Date
2012-05-30
Last Posted Date
2015-05-25
Lead Sponsor
Fraser Health
Registration Number
NCT01607671
Locations
🇨🇦

Jim Pattison Outpatient Care and Surgery Centre, 3C Neurology, Surrey, British Columbia, Canada

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

Phase 1
Terminated
Conditions
Sturge Weber Syndrome
Port-wine Mark
Interventions
Drug: Preservative free artificial tear gel.
Drug: Timolol
First Posted Date
2012-02-15
Last Posted Date
2019-03-21
Lead Sponsor
Wills Eye
Target Recruit Count
3
Registration Number
NCT01533376
Locations
🇺🇸

Wills Eye Institute, Philadelphia, Pennsylvania, United States

Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension

Phase 1
Conditions
Primary Open Angle Glaucoma
Ocular Hypertension
Interventions
Drug: Stage 1 - ATS907 - Dose 2
Drug: Stage 1 - ATS907 - Dose 1
Drug: Stage 1 - ATS907 - Dose 4
Drug: Stage 1 - Vehicle
Drug: Stage 2 - ATS907 - Dose A - to be selected based on Stage 1
Drug: Stage 2 - ATS907 - Dose B - to be selected based on Stage 1
Drug: Timoptic
Drug: Stage 1 - ATS907 - Dose 3
First Posted Date
2012-01-27
Last Posted Date
2012-11-01
Lead Sponsor
Altheos, Inc.
Target Recruit Count
180
Registration Number
NCT01520116

Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After LASIK: a Randomized Clinical Trial

Not Applicable
Completed
Conditions
Myopic Regression
Interventions
Drug: Placebo
Drug: Timolol
First Posted Date
2012-01-10
Last Posted Date
2012-01-10
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
45
Registration Number
NCT01506635
Locations
🇮🇷

Ophthalmic Research Center, Tehran, Iran, Islamic Republic of

Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma

Phase 4
Conditions
Normal Tension Glaucoma
Interventions
Drug: Brimonidine/Timolol mixed combination
Drug: Timolol
First Posted Date
2011-10-05
Last Posted Date
2011-10-05
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
22
Registration Number
NCT01446497
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Interaction Study of Timolol Eye Drops and Paroxetine Capsules

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Paroxetine
Drug: Placebo
Drug: timolol maleate
First Posted Date
2009-04-09
Last Posted Date
2010-01-28
Lead Sponsor
Santen Oy
Target Recruit Count
12
Registration Number
NCT00879099
Locations
🇫🇮

University of Helsinki, Department of Clinical Pharmacology, Helsinki, Biomedicum, Finland

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

Completed
Conditions
Open-angle Glaucoma
Ocular Hypertension
Interventions
Drug: timolol maleate
Drug: timolol hemihydrate
First Posted Date
2009-01-15
Last Posted Date
2015-03-06
Lead Sponsor
Vistakon Pharmaceuticals
Target Recruit Count
103
Registration Number
NCT00823043
Locations
🇺🇸

Eye Care of San Diego, San Diego, California, United States

A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom

Phase 3
Completed
Conditions
Ocular Hypertension
Open Angle Glaucoma
Interventions
Drug: PhXA41
Drug: timolol
First Posted Date
2008-09-11
Last Posted Date
2021-02-02
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
294
Registration Number
NCT00751049
Locations
🇬🇧

Pfizer Investigational Site, Sheffield, United Kingdom

A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension

Phase 3
Completed
Conditions
Glaucoma
Open Angle Glaucoma
Ocular Hypertension
Interventions
Drug: timolol
Drug: PhXA41
First Posted Date
2008-09-11
Last Posted Date
2011-03-25
Lead Sponsor
Pfizer
Target Recruit Count
268
Registration Number
NCT00751127
Locations
🇺🇸

Pfizer Investigational Site, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy